Cargando…

The efficacy of therapies for post-stroke depression in aging: An umbrella review

Post-stroke depression (PSD) is a common complication after stroke. PSD is associated with emotional disorders and psychological dependence, which are potential risk factors for stroke recurrence and suicidality. This study aimed to perform an umbrella review of therapies for PSD through a comprehen...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jinlu, Geng, Xiwen, Fan, Fangcheng, Fu, Xuyan, He, Shuaibing, Li, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446482/
https://www.ncbi.nlm.nih.gov/pubmed/36081895
http://dx.doi.org/10.3389/fnagi.2022.993250
_version_ 1784783650701705216
author Xie, Jinlu
Geng, Xiwen
Fan, Fangcheng
Fu, Xuyan
He, Shuaibing
Li, Tao
author_facet Xie, Jinlu
Geng, Xiwen
Fan, Fangcheng
Fu, Xuyan
He, Shuaibing
Li, Tao
author_sort Xie, Jinlu
collection PubMed
description Post-stroke depression (PSD) is a common complication after stroke. PSD is associated with emotional disorders and psychological dependence, which are potential risk factors for stroke recurrence and suicidality. This study aimed to perform an umbrella review of therapies for PSD through a comprehensive literature search. A systematic search was conducted in the PubMed and Web of Science by two independent authors. We examined the Hamilton Depression Scale (HAMD), Activities of daily living (ADL), Neurologic function as efficacy endpoints, and the incidence of adverse events as safety profiles. Seventeen eligible studies, including 267 clinical trials were included in this study. The results showed that High-Frequency Repetitive Transcranial Magnetic Stimulation (HfrTMS), Acupuncture/EA+conventional treatment, Escitalopram, Modified Sini San, Moxibustion, Xiaoyao Formula, Paroxetine, Chinese herbal medicine, Exercise, Citalopram, and Cognitive behavioral therapy are beneficial for improving the depression symptoms of patients with PSD. HfrTMS and Sertraline may have an impact on slowing the scores of activities of daily living or neurologic function. In addition, Acupuncture/EA+conventional, Escitalopram, Citalopram, Sertraline, and Fluoxetine showed no serious adverse events in PSD patients. Our study demonstrated that 11 treatment methods can effectively improve the condition of PSD patients.
format Online
Article
Text
id pubmed-9446482
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94464822022-09-07 The efficacy of therapies for post-stroke depression in aging: An umbrella review Xie, Jinlu Geng, Xiwen Fan, Fangcheng Fu, Xuyan He, Shuaibing Li, Tao Front Aging Neurosci Aging Neuroscience Post-stroke depression (PSD) is a common complication after stroke. PSD is associated with emotional disorders and psychological dependence, which are potential risk factors for stroke recurrence and suicidality. This study aimed to perform an umbrella review of therapies for PSD through a comprehensive literature search. A systematic search was conducted in the PubMed and Web of Science by two independent authors. We examined the Hamilton Depression Scale (HAMD), Activities of daily living (ADL), Neurologic function as efficacy endpoints, and the incidence of adverse events as safety profiles. Seventeen eligible studies, including 267 clinical trials were included in this study. The results showed that High-Frequency Repetitive Transcranial Magnetic Stimulation (HfrTMS), Acupuncture/EA+conventional treatment, Escitalopram, Modified Sini San, Moxibustion, Xiaoyao Formula, Paroxetine, Chinese herbal medicine, Exercise, Citalopram, and Cognitive behavioral therapy are beneficial for improving the depression symptoms of patients with PSD. HfrTMS and Sertraline may have an impact on slowing the scores of activities of daily living or neurologic function. In addition, Acupuncture/EA+conventional, Escitalopram, Citalopram, Sertraline, and Fluoxetine showed no serious adverse events in PSD patients. Our study demonstrated that 11 treatment methods can effectively improve the condition of PSD patients. Frontiers Media S.A. 2022-08-23 /pmc/articles/PMC9446482/ /pubmed/36081895 http://dx.doi.org/10.3389/fnagi.2022.993250 Text en Copyright © 2022 Xie, Geng, Fan, Fu, He and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Aging Neuroscience
Xie, Jinlu
Geng, Xiwen
Fan, Fangcheng
Fu, Xuyan
He, Shuaibing
Li, Tao
The efficacy of therapies for post-stroke depression in aging: An umbrella review
title The efficacy of therapies for post-stroke depression in aging: An umbrella review
title_full The efficacy of therapies for post-stroke depression in aging: An umbrella review
title_fullStr The efficacy of therapies for post-stroke depression in aging: An umbrella review
title_full_unstemmed The efficacy of therapies for post-stroke depression in aging: An umbrella review
title_short The efficacy of therapies for post-stroke depression in aging: An umbrella review
title_sort efficacy of therapies for post-stroke depression in aging: an umbrella review
topic Aging Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446482/
https://www.ncbi.nlm.nih.gov/pubmed/36081895
http://dx.doi.org/10.3389/fnagi.2022.993250
work_keys_str_mv AT xiejinlu theefficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT gengxiwen theefficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT fanfangcheng theefficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT fuxuyan theefficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT heshuaibing theefficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT litao theefficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT xiejinlu efficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT gengxiwen efficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT fanfangcheng efficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT fuxuyan efficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT heshuaibing efficacyoftherapiesforpoststrokedepressioninaginganumbrellareview
AT litao efficacyoftherapiesforpoststrokedepressioninaginganumbrellareview